https://www.globenewswire.com/news-release/2025/04/08/3057518/0/en/ZyVersa-Therapeutics-CEO-Issues-Shareholder-Letter-on-PARASOL-Recommendations-Expected-to-Reduce-Drug-Development-Barrier-for-Rare-Kidney-Disease-Focal-Segmental-Glomerulosclerosis.html
Very interesting note to SH from ZyVersa CEO about Parasol and FSGS. Not heard of this company before or it's lead drug.
Interesting also they say they are add on to FILSPARI, and make the same comment about proteinuria endpoint that it has to be over a 24 month period to be approvable by FDA. If DMX is doing the August interim, how many patients will have achieved 24 months of proteinuria data by then? Otherwise if it's not enough it's hard to see the August interim being accepted by FDA. Look forward to their ANN about FDA meeting which will hopefully clear some things up.
https://www.globenewswire.com/news-release/2025/04/08/3057518/0/e...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.035(6.25%) |
Mkt cap ! $308.6M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 57.0¢ | 52.0¢ | $1.033M | 1.931M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18732 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 30517 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |